New directions in antiarrhythmic drug therapy.
Cardiac arrhythmia causing sudden cardiac death is a serious worldwide public health problem. Antiarrhythmic agents have been available for therapy, but the conventional agents cause a high degree of intolerable side effects. The recent development of many new experimental antiarrhythmic agents has increased our capacity to effectively treat cardiac arrhythmias. Using a multifaceted approach of programmed electrical stimulation studies, drug level determinations, exercise testing and 24-hour ambulatory Holter monitoring, it can reasonably be decided which patient needs therapy and if therapy is going to be effective. Both aspects of the sudden death equation, ectopy frequency (triggering mechanism) and the ability to propagate sustained ventricular tachycardia (substrate), may be examined. Careful follow-up is needed to determine continued drug efficacy and the presence of side effects that may compromise patient compliance with therapy. If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate. A comprehensive approach to arrhythmia management may begin to reduce the high incidence of sudden death due to fatal arrhythmias.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000404:Ajmaline / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D044482:Benzeneacetamides; D015764:Bepridil; D001627:Bethanidine / Q000627:therapeutic use; D001950:Bretylium Tosylate / Q000627:therapeutic use; D003645:Death, Sudden / Q000517:prevention & control*; D004206:Disopyramide / Q000627:therapeutic use; D016700:Encainide; D005424:Flecainide; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D016293:Moricizine; D010640:Phenothiazines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy*; D016677:Tocainide; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000813:Anilides; D000889:Anti-Arrhythmia Agents; D044482:Benzeneacetamides; D010640:Phenothiazines; D010880:Piperidines; D011427:Propiophenones; D011759:Pyrrolidines; D000404:Ajmaline; D008801:Mexiletine; D016677:Tocainide; D016293:Moricizine; D001073:Aprindine; D011405:Propafenone; D015764:Bepridil; D001950:Bretylium Tosylate; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D005424:Flecainide; C015970:lorcainide; D011342:Procainamide; D000638:Amiodarone; D016700:Encainide; C024318:pirmenol; D001627:Bethanidine